




RealRate

PHARMACEUTICAL 2021

Moleculin Biotech Inc
Rank 236 of 394



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Moleculin Biotech Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Moleculin Biotech Inc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 83% points. The greatest weakness of Moleculin Biotech Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 66% points.

The company's Economic Capital Ratio, given in the ranking table, is 235%, being 21% points below the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	17,198
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,920
Liabilities, Non-Current	159
Other Assets	11,350
Other Compr. Net Income	34
Other Expenses	-2,146
Other Liabilities	8,192
Other Net Income	41
Other Revenues	0
Property and Equipment	483
Research and Development	12,757
Selling, General and Administrative Expense	6,785

Output Variable	Value in 1000 USD
Assets	29,031
Liabilities	11,271
Expenses	17,396
Revenues	0
Stockholders Equity	17,760
Net Income	-17,355
Comprehensive Net Income	-17,338
BaseVar	28,886
ECR before LimitedLiability	106%
Economic Capital Ratio	235%